๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Current race in the development of DAAs (direct-acting antivirals) against HCV

โœ Scribed by De Clercq, Erik


Book ID
121723201
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
472 KB
Volume
89
Category
Article
ISSN
0006-2952

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Current race in the development of DAAs
โœ De Clercq, Erik ๐Ÿ“‚ Article ๐Ÿ“… 2014 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 472 KB

The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir,